Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 10,000 shares at $151.71 ($1.5M) on 2018-11-26, disclosed to the SEC on 2018-11-28.
Open-market sale of $1.5M LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $151.71 | 1,556 | $236K | 16.0% |
| 2 | $152.49 | 1,644 | $251K | 16.9% |
| 3 | $154.00 | 1,500 | $231K | 15.6% |
| 4 | $155.30 | 600 | $93K | 6.3% |
| 5 | $156.45 | 200 | $31K | 2.1% |
| 6 | $138.08 | 949 |
| $131K |
| 8.9% |
| 7 | $138.83 | 1,170 | $162K | 11.0% |
| 8 | $140.13 | 300 | $42K | 2.8% |
| 9 | $141.69 | 500 | $71K | 4.8% |
| 10 | $143.08 | 500 | $72K | 4.8% |
| 11 | $143.92 | 200 | $29K | 1.9% |
| 12 | $144.97 | 100 | $14K | 1.0% |
| 13 | $147.06 | 300 | $44K | 3.0% |
| 14 | $147.99 | 81 | $12K | 0.8% |
| 15 | $149.46 | 200 | $30K | 2.0% |
| 16 | $151.55 | 200 | $30K | 2.0% |
| Total | $147.97 avg | 10,000 | $1.5M | 100% |
| Filing → |
| LOXO | SELL | 2018-10-05 | $2.0M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $2.8M | — | Filing → |
| LOXO | SELL | 2018-08-15 | $2.9M | — | Filing → |